Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Equecabtagene Autoleucel |
Chimeric Antigen Receptor T-Cell Therapy | Hematologic (Leukemia/Lymphoma/Myeloma) | ||
|
Molecule
Equecabtagene Autoleucel
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
||||
Erdafitinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Erdafitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Erlotinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Erlotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Everolimus |
mTOR Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Everolimus
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
||||
Famitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Famitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Farletuzumab Ecteribulin |
ADC | Solid Tumour | ||
|
Molecule
Farletuzumab Ecteribulin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Fedratinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Fedratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Fexagratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Fexagratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Fianlimab |
Anti-LAG-3 mAb | Solid Tumour | ||
|
Molecule
Fianlimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-LAG-3 mAb |
||||
Flumatinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Flumatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
Fluorine-18 FDG (Diagnostic) |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Fluorine-18 FDG (Diagnostic)
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Fluzoparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Fluzoparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Equecabtagene AutoleucelCellular Therapy (CAR-T) |
|
|
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
|
ErdafitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
ErlotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
EverolimusTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
|
FamitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
Farletuzumab EcteribulinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
FedratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
FexagratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
FianlimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-LAG-3 mAb |
|
FlumatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|
Fluorine-18 FDG (Diagnostic)Radiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
FluzoparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|